Menu Search
Equities

PharmaSGP Holding SE

PSG:MUN

PharmaSGP Holding SE

Actions
  • Price (EUR)23.40
  • Today's Change-0.600 / -2.50%
  • Shares traded730.00
  • 1 Year change+24.47%
  • Beta--
Data delayed at least 15 minutes, as of Nov 25 2024 07:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year PharmaSGP Holding SE grew revenues 17.80% from 85.82m to 101.10m. In addition the company has reduced the cost of goods sold as a percent of sales, selling, general and administrative expenses as a percent of sales and interest paid as a percent of sales. These improvements contributed to 37.17% net income growth from 11.95m to 16.40m.
Gross margin90.91%
Net profit margin16.59%
Operating margin23.73%
Return on assets13.64%
Return on equity56.49%
Return on investment18.34%
More ▼

Cash flow in EURView more

In 2023, PharmaSGP Holding SE increased its cash reserves by 24.89%, or 8.12m. The company earned 26.64m from its operations for a Cash Flow Margin of 26.35%. In addition the company used 866.00k on investing activities and also paid 17.65m in financing cash flows.
Cash flow per share2.30
Price/Cash flow per share10.18
Book value per share2.72
Tangible book value per share-2.47
More ▼

Balance sheet in EURView more

PharmaSGP Holding SE has a Debt to Total Capital ratio of 68.23%, a lower figure than the previous year's 219.18%.
Current ratio1.79
Quick ratio1.54
Total debt/total equity2.15
Total debt/total capital0.6823
More ▼

Growth rates in EUR

SmartText is unavailable
Div yield(5 year avg)--
Div growth rate (5 year)--
Payout ratio (TTM)89.61%
EPS growth(5 years)2.18
EPS (TTM) vs
TTM 1 year ago		28.71
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.